Rodrigo Rodriguez, general manager for Takeda’s Middle East cluster, discusses the company’s ambitions in the collective Saudi pharma market, which is expected to reach a size of USD 10 billion by 2025, the need for tailor-made programs for different countries in the Middle East, and how clinical trials and registry initiatives can help improve diagnosis timelines for rare disease patients. In addition, the Brazilian executive comments on the changes in Saudi’s procurement system, going beyond the Saudization of commercial roles, and improving the use of health data collection.
Looking at Vision 2030, it is evident that the country's healthcare system is shifting to quality-based care which means that there will be improvements in efficiency, quality, and infrastructure. Access to innovation will play an important role in the transformation of the country
